Charles Y. Lin is SR VP & RESEARCH & DEVELOPMENT at Kronos Bio, Inc. (KRON). They have made 1 open-market trade across 1 company since 2024, most recently 2024-02-21.
CIK 0002009852
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KRON | 234,603 | $206K |
Shares reported on the most recent Form 4, priced at the 2024-02-23 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KRON | SELL | 2024-02-21 | 2024-02-23 | $1.05 | $13K | +13.2% | +16.0% | -8.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.